# Fluid retention, swelling and pleural effusion on kinase inhibitors and MET-targeted drugs

Source: https://onco.cc/protocols/fluid-retention-and-effusions-on-kinase-inhibitors/  
OnCo record `fluid-retention-and-effusions-on-kinase-inhibitors` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some targeted cancer drugs make the body hold on to fluid: puffy eyelids, swollen ankles or, with dasatinib, fluid around the lungs. Swelling is managed with raised legs, support stockings, less salt, sometimes water tablets, and a lower dose if needed. Tell your cancer team promptly about rapid weight gain, new breathlessness, a dry cough, chest pain or one swollen, painful leg.

## Summary

Fluid retention is among the commonest side effects of imatinib, avapritinib (oedema in 72% of people with GIST in its label, 2% grade 3 or higher) and the MET inhibitors (with tepotinib, oedema led to a dose interruption in 28%, a reduction in 22% and permanent stopping in 8%), and pleural effusion is the characteristic problem of dasatinib (28% at 5 years in first-line use, ELN 2016). The guidance is thin: expert recommendations from the European LeukemiaNet without grades, a Novartis-funded review for MET inhibitors, and general dose-modification rows in the labels. The reader's own team's protocol comes first.

Watching: the imatinib label asks for regular weighing and for unexpected rapid weight gain to be investigated. In the CML studies oedema on imatinib was more likely at higher doses and over 65. Before blaming the drug, other causes are sought: the MET inhibitor review suggests a history, examination of the legs, and tests of kidney, liver and thyroid function or a marker of heart failure. Checking for a clot when one leg swells is ordinary practice that no source read here states.

Supportive care: leg elevation, compression stockings, exercise, less salt, skin and foot care, and a diuretic, which the MET inhibitor review says to consider when swelling interferes with quality of life. The evidence is experience, not trials: ELN says fluid retention on CML drugs is normally manageable and reversible with diuretics but that diuretics have limited benefit for periorbital oedema; the MET inhibitor review says management is empiric, and that in its authors' experience such measures are often only temporarily effective.

Label rules. Imatinib: withhold for severe fluid retention until resolved. Capmatinib and tepotinib: keep the dose at grade 2, and if it is intolerable consider withholding and resuming at a reduced dose; at grade 3 withhold until resolved and resume at a reduced dose; at grade 4 stop permanently. Amivantamab: withhold at grade 3 or 4 until grade 1 or baseline. Avapritinib: withhold at grade 3 or 4 until grade 2 or less. Dasatinib (adults): withhold for a severe reaction until it has resolved or improved, then resume as appropriate at a reduced dose. Apart from imatinib's, these are each label's general rule for adverse reactions.

Dasatinib pleural effusion: cough, breathlessness or chest pain prompt a chest X-ray. Management is interrupting or reducing the dose, with or without diuretics and short courses of steroids, and drainage when severe. ELN 2016 says the drug could be resumed at the same dose after a first episode has resolved, that the next lower dose is advisable after a second, and that switching is preferred if a relapse is symptomatic; recurrence occurs in roughly 70% of cases. ELN 2025 lists recurrent pleural effusions despite dose reductions among the side effects that call for a change of drug. Breathlessness or fainting not explained by an effusion should raise suspicion of pulmonary arterial hypertension.

Two products read on 18 November 2026. Telisotuzumab vedotin (US label only): withhold for grade 2 or higher peripheral oedema until grade 1 or less, resuming at the same dose after a first occurrence and at the next lower dose after a later one. Vimseltinib: periorbital oedema in 60% in the US label (3.6% at grade 3 or 4), with no rule written for it in either label; the US label gives dose reductions to 20 mg and then 14 mg twice weekly, and the EU SmPC says to withhold temporarily when the dose is not tolerated and restart at a reduced dose.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: oedema on targeted therapy; edema on TKIs; periorbital oedema on imatinib; puffy eyes on imatinib; swollen legs on capmatinib; MET inhibitor oedema; dasatinib pleural effusion; fluid retention on imatinib

## Connected records

- protocols: [Breathlessness and cough during anticancer drug treatment: what is excluded first and how the symptom is eased](https://onco.cc/protocols/breathlessness-and-cough-during-anticancer-treatment/), [Capillary leak syndrome on tagraxofusp, dinutuximab, aldesleukin and gemcitabine: monitoring and treatment](https://onco.cc/protocols/capillary-leak-syndrome-on-anticancer-drugs/), [Cognitive, mood and speech effects on lorlatinib, and cognitive effects on avapritinib](https://onco.cc/protocols/cognitive-and-mood-effects-on-lorlatinib-and-avapritinib/), [Differentiation syndrome on IDH, FLT3 and menin inhibitors and on tretinoin or arsenic trioxide: recognition and treatment](https://onco.cc/protocols/differentiation-syndrome-recognition-and-treatment/), [Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment](https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/), [Joint pain, muscle pain, cramps and raised creatine kinase on anticancer drugs](https://onco.cc/protocols/joint-and-muscle-pain-on-anticancer-drugs/), [Lymphoedema after breast cancer: risk reduction, surveillance, early compression and treatment](https://onco.cc/protocols/lymphoedema-risk-reduction-surveillance-and-treatment/), [Raised cholesterol and triglycerides, and weight gain, on lorlatinib, bexarotene and elacestrant](https://onco.cc/protocols/raised-lipids-and-weight-gain-on-lorlatinib-bexarotene-and-elacestrant/)
- drugs: [Amivantamab](https://onco.cc/drugs/amivantamab/), [Avapritinib](https://onco.cc/drugs/avapritinib/), [Capmatinib](https://onco.cc/drugs/capmatinib/), [Dasatinib](https://onco.cc/drugs/dasatinib/), [Imatinib](https://onco.cc/drugs/imatinib/), [Telisotuzumab vedotin](https://onco.cc/drugs/telisotuzumab-vedotin/), [Tepotinib](https://onco.cc/drugs/tepotinib/), [Vimseltinib](https://onco.cc/drugs/vimseltinib/)
- terms: [CTCAE toxicity grading (grade 3-4 adverse events)](https://onco.cc/terms/ctcae-grading/), [Venous thromboembolism (VTE)](https://onco.cc/terms/vte/)

---
JSON: https://onco.cc/api/v1/entities/fluid-retention-and-effusions-on-kinase-inhibitors.json